Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BLRX 
BioLineRx Ltd (BLRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: BLRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $26
1 Year Target Price $26
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 23.62% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.07M USD | Price to earnings Ratio - | 1Y Target Price 26 |
Price to earnings Ratio - | 1Y Target Price 26 | ||
Volume (30-day avg) 2 | Beta 0.89 | 52 Weeks Range 2.30 - 26.80 | Updated Date 09/16/2025 |
52 Weeks Range 2.30 - 26.80 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -45.34% | Operating Margin (TTM) -757.57% |
Management Effectiveness
Return on Assets (TTM) -15.36% | Return on Equity (TTM) -45.94% |
Valuation
Trailing PE - | Forward PE 93.46 | Enterprise Value 1373362 | Price to Sales(TTM) 0.98 |
Enterprise Value 1373362 | Price to Sales(TTM) 0.98 | ||
Enterprise Value to Revenue 0.08 | Enterprise Value to EBITDA 0.7 | Shares Outstanding 4262680 | Shares Floating 2450907651 |
Shares Outstanding 4262680 | Shares Floating 2450907651 | ||
Percent Insiders 4.08 | Percent Institutions 1.55 |
Upturn AI SWOT
BioLineRx Ltd
Company Overview
History and Background
BioLineRx Ltd. is a biopharmaceutical company focused on oncology. Founded in 2003, it initially focused on out-licensing early-stage drug candidates. Over time, it shifted its strategy to developing and commercializing its own pipeline, achieving a significant milestone with the FDA approval of APHARDAu00ae (motixafortide).
Core Business Areas
- Oncology Therapeutics: Focuses on developing and commercializing novel oncology therapies, primarily centered around its lead product, APHARDA (motixafortide).
Leadership and Structure
The leadership team consists of executives with experience in drug development, commercialization, and finance. The company structure is typical of a publicly traded biopharmaceutical company, with a board of directors overseeing management.
Top Products and Market Share
Key Offerings
- APHARDA (motixafortide): A CXCR4 inhibitor approved by the FDA for use in combination with filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. Market share data is still evolving as APHARDA is a relatively new product. Key competitors include drugs that stimulate hematopoietic stem cell mobilization, such as plerixafor (Mozobil) from Sanofi.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the oncology segment, is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. The market for stem cell mobilization therapies is driven by the increasing incidence of hematological malignancies and the growing demand for autologous stem cell transplantation.
Positioning
BioLineRx positions itself as a company focused on innovative oncology therapies. APHARDA provides a novel option for stem cell mobilization, addressing a specific need in multiple myeloma treatment.
Total Addressable Market (TAM)
The global stem cell mobilization market is estimated to be in the hundreds of millions USD annually and is expected to grow. BioLineRx is positioned to capture a share of this market with APHARDA.
Upturn SWOT Analysis
Strengths
- FDA-approved product (APHARDA)
- Novel mechanism of action (CXCR4 inhibition)
- Strong IP protection for APHARDA
Weaknesses
- Reliance on a single product (APHARDA)
- Limited commercial infrastructure
- High operating expenses associated with drug development and commercialization
- Need for additional financing
Opportunities
- Expansion of APHARDA label to other indications
- Strategic partnerships for commercialization in new territories
- Development of new pipeline candidates
Threats
- Competition from existing stem cell mobilization therapies
- Potential for generic versions of APHARDA after patent expiry
- Unfavorable regulatory decisions
- Failure to secure additional financing
Competitors and Market Share
Key Competitors
- SNY
- AMGN
Competitive Landscape
BioLineRx faces competition from established pharmaceutical companies with existing stem cell mobilization therapies. APHARDA's novel mechanism of action provides a competitive advantage.
Growth Trajectory and Initiatives
Historical Growth: Growth has been tied to clinical trial progress and regulatory approvals. The approval of APHARDA marks a significant growth milestone.
Future Projections: Future growth depends on the successful commercialization of APHARDA, potential label expansion, and development of new pipeline candidates. Analyst projections vary.
Recent Initiatives: Recent initiatives include launching APHARDA in the US market, pursuing partnerships for ex-US commercialization, and advancing other pipeline programs.
Summary
BioLineRx is a biopharmaceutical company with an FDA-approved product, APHARDA, targeting stem cell mobilization. The company faces challenges related to commercialization, competition, and financing. Success hinges on APHARDA's market penetration and future pipeline development. Securing partnerships and managing cash flow will be crucial.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Press releases
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data is estimated and may vary. Please consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioLineRx Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2011-07-25 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 28 | Website https://www.biolinerx.com |
Full time employees 28 | Website https://www.biolinerx.com | ||
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.